Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Concurrent Investment Advisors LLC

Key Points

• Concurrent Investment Advisors LLC increased its holdings in Regeneron Pharmaceuticals by 136.4%, now owning 1,622 shares valued at approximately $852,000.
• Regeneron reported an earnings per share (EPS) of $12.89 for the last quarter, surpassing analysts' expectations of $8.43, and generated $3.68 billion in revenue.
• The company declared a quarterly dividend of $0.88 per share, representing an annualized dividend of $3.52 and yielding 0.6%.

Concurrent Investment Advisors LLC increased its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 136.4% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,622 shares of the biopharmaceutical company's stock after purchasing an additional 936 shares during the quarter. Concurrent Investment Advisors LLC's holdings in Regeneron Pharmaceuticals were worth $852,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of REGN. Kingswood Wealth Advisors LLC grew its holdings in shares of Regeneron Pharmaceuticals by 1.8% in the first quarter. Kingswood Wealth Advisors LLC now owns 1,084 shares of the biopharmaceutical company's stock valued at $681,000 after purchasing an additional 19 shares in the last quarter. Creative Financial Designs Inc. ADV boosted its position in Regeneron Pharmaceuticals by 9.5% in the 1st quarter. Creative Financial Designs Inc. ADV now owns 220 shares of the biopharmaceutical company's stock valued at $139,000 after buying an additional 19 shares during the period. Private Trust Co. NA grew its stake in shares of Regeneron Pharmaceuticals by 13.1% in the first quarter. Private Trust Co. NA now owns 164 shares of the biopharmaceutical company's stock worth $104,000 after acquiring an additional 19 shares in the last quarter. Proficio Capital Partners LLC increased its position in shares of Regeneron Pharmaceuticals by 6.2% during the first quarter. Proficio Capital Partners LLC now owns 327 shares of the biopharmaceutical company's stock worth $207,000 after acquiring an additional 19 shares during the period. Finally, Cove Private Wealth LLC increased its position in shares of Regeneron Pharmaceuticals by 4.5% during the first quarter. Cove Private Wealth LLC now owns 460 shares of the biopharmaceutical company's stock worth $292,000 after acquiring an additional 20 shares during the period. Hedge funds and other institutional investors own 83.31% of the company's stock.

Regeneron Pharmaceuticals Stock Performance

Shares of Regeneron Pharmaceuticals stock opened at $569.17 on Friday. The company has a quick ratio of 3.72, a current ratio of 4.60 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,013.09. The firm's 50 day moving average is $574.34 and its two-hundred day moving average is $563.16. The firm has a market capitalization of $60.33 billion, a P/E ratio of 14.34, a P/E/G ratio of 1.85 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.43 by $4.46. The business had revenue of $3.68 billion during the quarter, compared to analysts' expectations of $3.30 billion. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company's revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $11.56 EPS. Research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th were issued a dividend of $0.88 per share. The ex-dividend date of this dividend was Monday, August 18th. This represents a $3.52 annualized dividend and a dividend yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.87%.

Analyst Ratings Changes

A number of research firms recently issued reports on REGN. Canaccord Genuity Group reiterated a "buy" rating and issued a $850.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday. Morgan Stanley lowered their price objective on Regeneron Pharmaceuticals from $761.00 to $756.00 and set an "overweight" rating for the company in a research report on Friday, October 10th. Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a report on Thursday, August 14th. BMO Capital Markets boosted their price target on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an "outperform" rating in a report on Monday, August 4th. Finally, Raymond James Financial raised shares of Regeneron Pharmaceuticals to a "moderate buy" rating in a research report on Tuesday, September 2nd. Three analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $817.88.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.